Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Embolism | 3 | 2019 | 174 | 1.450 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 125 | 0.580 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 165 | 0.570 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 183 | 0.570 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2019 | 47 | 0.560 |
Why?
|
| Physicians | 1 | 2022 | 443 | 0.550 |
Why?
|
| Heart Arrest | 1 | 2019 | 162 | 0.530 |
Why?
|
| Echocardiography, Doppler | 1 | 2016 | 133 | 0.510 |
Why?
|
| Heart Ventricles | 2 | 2019 | 253 | 0.510 |
Why?
|
| Azathioprine | 1 | 2010 | 28 | 0.340 |
Why?
|
| Gastrointestinal Agents | 1 | 2010 | 36 | 0.330 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 56 | 0.330 |
Why?
|
| Intensive Care Units | 3 | 2022 | 458 | 0.310 |
Why?
|
| Crohn Disease | 1 | 2010 | 117 | 0.300 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 369 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 860 | 0.240 |
Why?
|
| Acute Disease | 2 | 2017 | 671 | 0.240 |
Why?
|
| Pulmonary Artery | 2 | 2020 | 91 | 0.200 |
Why?
|
| Vascular Resistance | 2 | 2019 | 48 | 0.200 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 16 | 0.190 |
Why?
|
| Hemodynamics | 2 | 2019 | 239 | 0.180 |
Why?
|
| Echocardiography | 3 | 2019 | 462 | 0.170 |
Why?
|
| Prostaglandins I | 1 | 2020 | 2 | 0.170 |
Why?
|
| Acetamides | 1 | 2020 | 13 | 0.170 |
Why?
|
| Arterial Pressure | 1 | 2020 | 23 | 0.170 |
Why?
|
| Drug Substitution | 1 | 2020 | 42 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 173 | 0.170 |
Why?
|
| Pyrazines | 1 | 2020 | 33 | 0.170 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2019 | 4 | 0.160 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2019 | 14 | 0.160 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 160 | 0.160 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 61 | 0.160 |
Why?
|
| Survival Rate | 2 | 2021 | 812 | 0.150 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 301 | 0.150 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 179 | 0.150 |
Why?
|
| Humans | 12 | 2022 | 61135 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 93 | 0.150 |
Why?
|
| Registries | 1 | 2021 | 807 | 0.150 |
Why?
|
| Adult | 5 | 2021 | 16196 | 0.140 |
Why?
|
| Middle Aged | 6 | 2021 | 16831 | 0.140 |
Why?
|
| Heart Function Tests | 1 | 2017 | 14 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2019 | 272 | 0.140 |
Why?
|
| Male | 8 | 2021 | 28692 | 0.140 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 27 | 0.140 |
Why?
|
| Retrospective Studies | 2 | 2019 | 6186 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 2404 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2017 | 263 | 0.120 |
Why?
|
| Lung | 1 | 2019 | 916 | 0.110 |
Why?
|
| Female | 7 | 2021 | 31658 | 0.110 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2016 | 305 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 382 | 0.100 |
Why?
|
| Aged | 6 | 2021 | 14129 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 332 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2016 | 410 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 1598 | 0.100 |
Why?
|
| Dendritic Cells | 1 | 2016 | 796 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2017 | 1946 | 0.080 |
Why?
|
| Infliximab | 1 | 2010 | 55 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2010 | 116 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 932 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 99 | 0.080 |
Why?
|
| Cardiac Catheterization | 2 | 2019 | 256 | 0.070 |
Why?
|
| Nitrofurantoin | 1 | 2006 | 9 | 0.070 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2006 | 4 | 0.070 |
Why?
|
| Liver Failure, Acute | 1 | 2006 | 12 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2019 | 847 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2020 | 5620 | 0.050 |
Why?
|
| United States | 1 | 2016 | 7645 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2020 | 3182 | 0.050 |
Why?
|
| Saudi Arabia | 1 | 2021 | 4 | 0.050 |
Why?
|
| International Agencies | 1 | 2021 | 7 | 0.050 |
Why?
|
| Receptors, Epoprostenol | 1 | 2020 | 1 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2020 | 21 | 0.040 |
Why?
|
| Iloprost | 1 | 2019 | 3 | 0.040 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2019 | 33 | 0.040 |
Why?
|
| Epoprostenol | 1 | 2019 | 14 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 5554 | 0.040 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2019 | 19 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 532 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 344 | 0.040 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2019 | 129 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 422 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 1631 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 470 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2016 | 393 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 849 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1347 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 3658 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 1675 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1238 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4414 | 0.020 |
Why?
|
| Adolescent | 1 | 2021 | 6029 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 939 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 10646 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 20116 | 0.010 |
Why?
|